Allergan's Twice-Daily Vuity Study Hits Main Endpoint in Presbyopia
April 05 2022 - 9:29AM
Dow Jones News
By Colin Kellaher
AbbVie Inc.'s Allergan unit on Tuesday said a Phase 3 study of
twice-daily use of its Vuity eye drops met the main endpoint in
adults with age-related blurry near vision, also known as
presbyopia.
Allergan said the study, which met the primary endpoint of
improving near vision without compromising distance vision at hour
nine on day 14, would form the basis of an application for expanded
approval of Vuity that the company plans to file with the U.S. Food
and Drug Administration in the second quarter.
The FDA last year approved once-daily use of Vuity as the first
and only eye drop to treat age-related blurry near vision in
adults.
Allergan, which AbbVie acquired in 2020 in a $63 billion deal,
said roughly 128 million people in the U.S. experience presbyopia,
which reduces the eye's ability to focus on near objects and
usually affects people after age 40.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 05, 2022 09:14 ET (13:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024
